Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal
Brain · 03.07.2023 · 146 (7) · 2711-2716
DOI: 10.1093/brain/awac394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 31.10.2022. Verfasst von Michael Benatar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Miami, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, Motor Neurone Disease Association, U.S. National Institutes of Health.
Abstract (Originalsprache)
Interest in amyotrophic lateral sclerosis (ALS) biomarkers has grown exponentially over the course of the last 25 years, with great hope that they might serve as tools to facilitate the development of meaningful therapies for this otherwise inexorably progressive and invariably fatal disease. Effective use of biomarkers, however, requires an understanding of what it means for them to be ‘fit-for-purpose’ as well as an appreciation of the nuances of the clinical context(s) in which they will be applied. Neurofilament light chain (NfL) has emerged as a leading candidate with enormous potential to aid ALS therapy development; it is, however, also profoundly misunderstood. Within the conceptual framework of the BEST (Biomarkers, EndpointS, and other Tools) Resource, developed by the National Institutes of Health and the Food and Drug Administration in the USA, we consider the evidence supporting the use of NfL for a variety of purposes in different clinical contexts. We conclude that: (i) it may serve as a susceptibility/risk biomarker in populations at elevated risk for ALS; (ii) it has value as a prognostic biomarker when measured early in the course of established disease, empowering stratification or dynamic randomization to amplify the signal-to-noise ratio of promising therapeutics; and (iii) there is sufficient evidence to support the use of a reduction in NfL in response to an experimental therapeutic as a pharmacodynamic biomarker that may aid in phase 2 trial go/no-go decisions. Moreover, the basis for expecting that a reduction in NfL is a reasonably likely surrogate end-point (i.e. reasonably likely to predict clinical benefit—which may be more than simply survival) is nuanced, and depends on when in the course of disease the experimental therapeutic is administered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Miami, Miami, FL 33136, USA.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.
ORCID-Profile: Michael Benatar, Martin R Turner
Förderung
- NINDS NIH HHS
- Motor Neurone Disease Association
- U.S. National Institutes of Health
- CReATe Consortium
- U.K. Motor Neurone Disease Association
Zitieren
APA
Benatar, M., Wuu, J., & Turner, M. R. (2023). Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. Brain, 146(7), 2711-2716. https://doi.org/10.1093/brain/awac394
Vancouver
Benatar M, Wuu J, Turner MR. Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. Brain. 2023;146(7):2711-2716. doi:10.1093/brain/awac394
BibTeX
@article{Benatar2023,
author = {Benatar, Michael and Wuu, Joanne and Turner, Martin R},
title = {Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal},
journal = {Brain},
year = {2023},
volume = {146},
number = {7},
pages = {2711--2716},
doi = {10.1093/brain/awac394}
}
EUVIMED